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Mesenchymal stem or stromal cells (MSC) have proven immunomodulatory properties
toward B cell activation and induce regulatory B cells (Breg), through a dual mechanism
of action that relies both on cell contact and secreted factors. One of them are
MSC-derived extracellular vesicles (EVs), membrane nanovesicles that mediate cell
communication and typically reflect the phenotype of the cell of origin. MSC-EVs could
resemble MSC functions, and are being contemplated as an improved alternative to
the MSC-based immunomodulatory therapy. In the present work, we focused on the
factors secreted by MSC and aimed to elucidate the putative role of MSC-EVs in the
immunomodulation of B cells. EVs and soluble protein-enriched fractions (PF) were
isolated from MSC-conditioned medium (CM) using size-exclusion chromatography
(SEC) and their capacity to modulate B cell activation, induction of Breg and B cell
proliferation was compared to that of the whole MSCs. Co-culture with MSC or
unfractionated CM induced naïve and CD24hiCD38hi, IL-10 producing (Breg) phenotypes
on B cells while not affecting proliferation. MSC-PF had a comparable effect to MSCs,
inducing a naïve phenotype, and even though they did not induce the shift toward a
CD24hiCD38hi population, MSC-PF fostered IL-10 production by B cells. Conversely,
MSC-EVs failed to promote naïve B cells and to reduce memory B cells. MSC-EVs
induced CD24hiCD38hi B cells to a similar extent of that of MSC, but not bona fide Bregs
since they did not produce IL-10. Our results show that B cell modulation by MSC is
partially mediated by soluble factors other than EVs.
Keywords: mesenchymal stromal cells, exosome, regulatory B cell, immunosuppression, memory B cell, Ev
isolation
INTRODUCTION
Mesenchymal stem or stromal (MSC) are immunomodulatory toward numerous immune cell types
in vitro as well as in vivo (1–3). We recently showed their ability to induce regulatory (Breg) and
naïve B cells while reducing activated and memory B cells (4). While the exact mechanism of action
remains unclear (5), both cell-contact and secreted factors are needed for MSC modulation of B
cells (6, 7). Some cytokines and growth factors have been identified as key mediators amid secreted
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factors, but more recently the focus has been put on
extracellular vesicles (EVs). EVs are membrane nanovesicles
that carry molecules reflecting the phenotype and functions
of the cells of origin (8). MSC-derived EVs have been shown
to emulate their effect on B cells and other immune cells
(9–11). However, parameters related to the EV isolation method
-including purity- are key to downstream analyses. Widely used
techniques such as ultracentrifugation (UC) or precipitating
agents-based methods cause the co-precipitation of EVs with
other potentially confusing soluble molecules (12), whilst size-
exclusion chromatography (SEC) is being considered the method
of choice to highly enrich functional EVs (13).
The purpose of the present study is to use SEC to dissect the
role of MSC-EV from secreted soluble factors in order to deepen
in the mechanisms of B cell immunomodulation by MSC.
MATERIALS AND METHODS
Mesenchymal Stem or Stromal Cell
Isolation and Cell Culture
Subcutaneous adipose tissue was obtained from patients
undergoing heart surgery in University Hospital Germans Trias
i Pujol (HUGTiP). Informed consent was obtained from all
subjects, and the study protocol conformed to the principles
outlined in the Declaration of Helsinki. Mesenchymal stem or
stromal cells (MSC) were isolated from fat tissue as previously
described (4, 14). MSC, which were used in passages between 3
and 10, were cultured in αMEM (Sigma Aldrich) supplemented
with 10% FBS (Lonza), penicillin (100 IU/ml, Cepa S.L., Madrid,
Spain), streptomycin (100 mg/ml, Normon Laboratories S.A.,
Madrid, Spain) and 2mM L-Glutamine (Sigma Aldrich).
Preparation of Conditioned Medium
Two million MSC were seeded in cell culture flasks with 15ml
of complete medium depleted from fetal bovine serum (FBS)-
derived EVs (11). To deplete medium from FBS-EVs, 20%
FBS complete medium (αMEM +1% P/S +2mM L-Glutamine)
was ultracentrifuged at 100,000 × g for 16 h in polypropylene
ultracentrifugation tubes (Beckman coulter, Brea, CA). The
supernatant was collected and filtered through a 0.22µm filter
(Sarstedt, Germany) to sterilize the medium, which was finally
diluted with αMEM medium to the final concentration of 10%
FBS for cell culture. After 48 h, the medium was collected and
centrifuged at 400 × g and 2,000 × g to eliminate cells and cell
debris, respectively, to obtain MSC-conditioned medium (CM).
Extracellular Vesicles and Soluble Protein
Separation and Analysis
Size-Exclusion Chromatography
MSC-CM was concentrated using a 100 kDa ultrafiltration unit
(Amicon Ultra, Millipore, Millerica MA) and fractioned by
SEC using columns of 1ml sepharose CL-2B (Sigma Aldrich).
Figure 1A schematically depicts the followed protocol, which can
be read in detail in Monguió-Tortajada et al. (15).
Bead-Based Flow Cytometry
The EV-enriched SEC fractions were determined by beads-
based flow cytometry according to the presence of CD9 and
CD90 following the previously described procedure (11, 15)
(Figure 1B). Briefly, EVs were coupled to 4µm aldehyde/sulfate
latex microspheres and were then labeled with the fluorochrome-
conjugated antibodies anti-CD90-PE-Cy7 or indirectly labeled
with the primary antibodies anti-CD9 (Clone VJ1/20) and or
the IgG isotype control and secondary antibody FITC-conjugated
Goat F(ab’)2 Anti-Mouse IgG. The MSC-EV fractions with the
highest CD9 and CD90 MFI were pooled to obtain highly
enriched MSC-EV preparations.
Cryo-Transmission Electron Microscopy (Cryo-TEM)
The presence of EVs in EV-enriched fractions was confirmed
by cryo-transmission electron microscopy (cryo-TEM) as
previously described (16).
Protein Quantification
Protein elution was checked by reading the absorbance
(Abs.) at 280 nm of each fraction using Nanodrop R© ND-1000
(Thermo Scientific) to pool fractions with the highest protein
concentration and obtain MSC-PF preparations.
B Cells
Isolation From Tonsils
Tonsils were obtained from children undergoing routine
tonsillectomy after the informed consent of their legal tutors
(HUGTiP). The study protocol followed the principles of
the Declaration of Helsinki. To obtain B cells, tonsils were
mechanically disaggregated with a scalpel, washed with
PBS, mononuclear cells were isolated by ficoll differential
centrifugation (GE Healthcare) and frozen (liquid N2). For the
experiments, tonsil cells were thawed and negatively sorted
(MACS, Miltenyi Biotech) to obtain the CD43− population
(mature inactivated B cells).
Activation and Culture
One hundred-thousand B cells were seeded in flat bottom 96 well
plates, T-cell-like-stimulated with IL-2/anti-IgM/anti-CD40 and
co-cultured with 10,000 MSC for 7 days in a 10:1 B:MSC ratio as
previously described (4, 7).
B cells were also cultured with MSC-CM, MSC-EV, or MSC-
PF. Of each condition, 100µl of MSC-EV orMSC-PF were added
to the culture. This volume corresponded to EVs and PF secreted
by 50,000 MSC which is 5 times the amount of MSC added in
the B cell-MSC co-culture. In the dose-dependency experiments,
half (50 µl) or one tenth (10 µl) of the initial volume of CM or
PF conditions were used.
B Cell Subsets and Proliferation Assessment by
Flow Cytometry
After 7 days, B cells were collected and processed for flow
cytometric analysis to analyze B cell populations (FACS
Canto II, BD Biosciences) as previously described (4, 7).
Viability was assessed by 7AAD staining (BD Biosciences)
and quantified as CD19+7AAD− cells among the lymphocyte
population. In separate experiments, B cells were labeled with
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FIGURE 1 | (A) Workflow of the methodology used to isolate MSC-EV and MSC-PF by SEC from MSC-CM. (1) Supernatant was collected after 48 h of MSC culture
and (2) sequentially centrifuged at 400 × g for 5min and at 2,000 × g for 10min to exclude cells and cell debris, respectively. The obtained MSC-CM was partially
kept for experimental use in B cell culture and the rest was then (3) concentrated by 100 kDa ultrafiltration. (4) Concentrated MSC-CM was loaded into a 1ml SEC
(Continued)
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FIGURE 1 | sepharose column and (5) 100 µl fractions (up to 20) were collected immediately after loading. (B) Representative plot showing the SEC elution profile
according to protein concentration and median fluorescence intensity (MFI) of EV markers of each SEC fraction. Fractions with the highest CD9 and CD90 MFI or were
pooled together, similarly to fractions with the highest protein concentration, to obtain the MSC-EV or MSC-PF preparations, respectively. (C) Cryo-TEM was used to
analyze MSC-EV size and morphology. Black arrows point EV in the preparations over the TEM grid. Scale bars = 0.5µm (left) and 0.2µm (right). (D) Gating strategy
followed to define B cell subsets by flow cytometry. Doublets and debris were excluded by FSC-A/FSC-H and FSC-A/SSC-A, respectively, by gating on singlets and
lymphocyte populations. Alive B cells were further gated as CD19+7AAD−, from which each subset was defined: naïve (CD27− IgD+), non-switched memory
(CD27+ IgD+), switched memory (CD27+ IgD−), activated/memory (CD24hiCD38int/lo), and Breg (CD24hiCD38hi). Bottom right panel shows a representative
proliferation plot where cell generations are indicated with dashed lines. For analysis, the percentages of total proliferated cells (G1 onwards) and G4+ proliferated
cells (G4 onwards) were calculated.
FIGURE 2 | Flow cytometry was used to measure (A) percentages of alive B cell (CD19+7AAD−); (B) percentages of B cell subsets: naïve (CD27− IgD+),
non-switched memory (CD27+ IgD+), switched memory (CD27+ IgD−); (C) the percentage of Breg (CD24hiCD38hi) and the ratio between Breg (CD24hiCD38hi) and
activated/memory (CD24hiCD38int/lo) for each condition, and (D) in a dose-dependency experiment for PF and CM conditions. Each dot represents a different
combination of MSC and B cells donors. Statistical significance (p < 0.05) was determined by Kruskall-Wallis with Dunn’s multi-comparison test (*p ≤ 0.05, **p ≤
0.01, ***p ≤ 0.001, ****p ≤ 0.0001). MSC, mesenchymal stem cells; CM, conditioned medium; EV, extracellular vesicles; PF, protein fraction.
Violet CellTrace (Invitrogen) for 20min at 37◦C to analyze
proliferation by dye dilution. Figure 1D shows the gating
strategy followed.
IL-10 and TNFα Quantification by ELISA
After co-culture, supernatants were harvested and stored at
−80◦C for later IL-10 and TNFα quantification using dedicated
ELISA kits (U-CyTech).
Data Analysis
All the experiments were performed with an allogenic co-culture
of MSC and B cells from eleven and five different donors,
respectively. Technical duplicates were used. Flow cytometry data
was analyzed by FlowJo v10 software (FlowJo LLC, Ashland,
OR). Statistical analysis was performed with Prism v6 software
(GraphPad, La Jolla, CA). Kruskall-Wallis with Dunn’s multi-
comparison test was used to determine statistical differences
between groups (p < 0.05 was considered significant).
RESULTS
EV Isolation and Analysis
MSC-CM obtained after 48 h of culture was collected
concentrated and fractionated by SEC. Fractions eluted
from SEC were evaluated for CD9 and CD90, which are known
EV (8) and MSC-EV markers (17), respectively (Figure 1A).
As previously described by our group (11), we consistently
observed that SEC EV-enriched fractions were free from the bulk
of soluble proteins, that eluted in later fractions. MSC-EV were
further characterized by Cryo-TEM, confirming the presence of
nanosized EV (Figure 1C).
B Cell Survival Relies on
Cell-To-Cell Contact
We have previously shown that MSC increase B cell survival
compared to non-stimulated B cells but also compared to T
cell-like activated B cells (IL-2/anti-IgM/anti-CD40) (4). In the
current setting, the number of living B cells (CD19+7AAD−)
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was significantly increased in the co-cultures with MSC but
not in the other conditions, compared to stimulated B cells
alone (Figure 2A).
B Cell Plasticity Mediated by MSC Is
Independent of MSC-EVs
B cell population analysis by flow cytometry revealed that MSC-
CM andMSC-PF retained B cells in a naïve state similarly toMSC
contact, and reduced non-switched and switchedmemory B cells.
MSC-EV did not change B cell populations of stimulated B cells
(Figure 2B).
The MSC-PF but Not MSC-EV Is Partially
Responsible of Breg Induction
We next assessed the induction of Breg, phenotypically defined
here as CD24hiCD38hiCD19+ B cells and by secretion of IL-10
and low secretion of TNFα. The CD24hiCD38hi phenotype was
only significantly induced by MSC co-culture. Since activated
and memory B cells represent the CD24hiCD38int/lo subset,
we defined the ratio CD24hiCD38hi/CD24hiCD38int/lo as an
index between transitional immunosuppressive (CD24hiCD38hi)
and inflammatory activated/memory (CD24hiCD38int/lo) B
cell populations. In this case, MSC significantly generated
a higher immunoregulatory ratio than any of the other
conditions (Figure 2C).
To further confirm that the paracrine effect of MSC on
Breg polarization is mediated by the PF of the CM, a
dose-dependency experiment was performed. We observed
that the percentage of CD24hiCD38hi cells and the ratio
CD24hiCD38hi/CD24hiCD38int/lo were higher when the highest
dose of PF and CM was added to cells, showing that this effect
is related to the CM and its soluble protein-enriched fractions
(Figure 2D). Moreover, the PF as well as the CM could increase
the percentage of non-switched and switched memory subsets in
a dose-dependent manner (data not shown).
In line, the IL-10 concentration of MSC co-culture condition
was also significantly higher than in any other condition,
except for MSC-PF. MSC-PF significantly induced more IL-
10 secretion than MSC-EV and B cells alone. Noticeably,
TNFα was secreted at very low concentrations in all conditions
(<20 pg/ml) (Figure 3).
Assessment of B Cell Subsets Proliferation
We also compared the effect of whole MSC with their secreted
factors in terms of B cell subsets proliferation. In our setting,
after 7 days >80% of B cells proliferated in all conditions with
few changes between groups (data not shown), so we focused
on the study of 4th generation onwards proliferation (G4+).
MSC co-culture allowed B cell proliferation G4 onwards whilst
MSC-CM and its derived fractions did not reach the same
percentage, even though the differences did not reach statistical
significance. We further observed a trend of MSC-EV compared
MSC-PF to reduce proliferation of naïve, non-switched
memory B cells and Bregs while increasing switched memory
proliferation (Figure 4).
FIGURE 3 | Concentration of IL-10 and TNFα in the culture medium after 7
days of B cell culturing with the different conditions measured by ELISA. Each
dot represents a different combination of MSC and B cells donors. Statistical
significance (p < 0.05) was determined by Kruskall-Wallis with Dunn’s
multi-comparison test (*p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001). MSC,
mesenchymal stem cells; CM, conditioned medium; EV, extracellular vesicles;
PF, protein fraction.
DISCUSSION
In the present work we studied the role of the MSC secreted
factors on B cell immunomodulation. We isolated EVs by
SEC, which allows to obtain purer EV preparation to properly
discriminate it from the non-EV soluble fraction.
Ultracentrifugation (UC) without any extra purification step
has been the solely and most widely used method for EV
isolation, as reflected in the majority of published articles.
However, UC is not an appropriate method to isolate EV
since it affects the biophysical properties and co-precipitate
EV with other particles (proteins, membrane fractions. . . ) that
are interfering with the subsequent molecular or functional
analyses (18–20). Recently, more refined techniques for EV
purification have made their way into the field which are slowly
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FIGURE 4 | Percentage of proliferation from the 4th generation onwards (G4+ proliferation) of the different B cell subsets measured by dilution of Violet CellTrace dye
by flow cytometry. The different subsets were gated from alive B cells (CD19+7AAD−). Naïve, CD19+CD27− IgD+; non-switched memory, CD27+ IgD+; switched
memory, CD27+ IgD−; Breg, CD24hiCD38hi. No statistically significant differences were found between conditions by Kruskall-Wallis with Dunn’s
multi-comparison test.
changing the paradigm about the properties and functional
characteristics of EV. Within these methods, SEC stands out
for its better preservation, higher yield and purity, and ease
for EV isolation (12, 21). Several groups have assessed the
differences between UC and SEC for downstream analyses,
concluding that UC co-precipitate EVs and soluble proteins
hampering the discrimination of their individual effect in
functional studies (11, 13, 22, 23).
Conditioned medium (MSC-CM) was fractionated by SEC to
obtain EV-enriched and non-EV soluble protein fractions, and
their distinct effect on B cell subsets and proliferation after T-
cell like activation was analyzed. MSC-CM and MSC-PF had
a comparable immunomodulatory effect to that of MSC on
B cells—increasing the proportion of naïve B cells and IL-10
production and reducing memory B cell phenotype proportions.
In contrast, MSC-EV did not exert any effect on activated B cells.
Our results contrast with those obtained before that postulate
MSC-EV as important mediators for B cell immunomodulation
(9, 24). One of the key points of this difference is the method used
to isolate and purify the EVs.
The effect of MSC-PF is similar but to a lower level than
MSC co-culture. This can be due to the fact that the modulation
of B cells by MSC is partially cell-contact dependent, but it
also could be explained by differences in B cells’ stimulation
time frame, since factors are secreted continuously throughout
7 days in the co-culture. To counterbalance this effect, and
because a well-defined quantification of EVs is missing in the
field, the amount of MSC-EV and MSC-PF used was coming
from a proportionally higher number of cells than those used
in the co-culture setting. This approach avoids the potential
underestimation of the effect of EV or soluble factors due to an
insufficient amount.
The lack of unique markers for Breg complicates their
analysis. While the transitional phenotype CD24hiCD38hi
appears as one of the most accepted, IL-10 production
is still the key feature to define Breg. In our hands, the
transitional phenotype did not fully correlate with IL-10
secretion, since the percentage of CD24hiCD38hi was only
increased in the MSC co-culture setting compared to B
cells alone, while IL-10 concentration was significantly
increased in both the co-culture as well as with MSC-PF.
However, we experimentally observed that the ratio transitional
(CD24hiCD38hi)/activated-memory B cells (CD24hiCD38int/lo)
correlated better with IL-10 production. This argues for the
hypothesis that a favorable balance between immunomodulatory
and pro-inflammatory phenotypes is needed for
immunomodulation, rather than fostering immunomodulatory
phenotypes alone.
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Proliferation experiments rendered a similar percentage
of proliferating cells in B cells alone and MSC conditions.
However, as the viability of B cells alone was significantly
lower, the total number of proliferated B cells was higher
in the MSC co-culture. Results were not significantly
different between MSC-CM or its derived fractions, but
the mean proliferation percentage was lower than in the
co-culture, suggesting a cell-contact based mechanism to
fulfill an optimal MSC conditioning. Still, we observed a
trend of MSC-CM and MSC-PF to better reflect the effect of
MSC co-culture compared to MSC-EV supporting the idea
that MSC-PF better reflects the immunomodulatory effect
of MSC.
Using SEC as one of the most refined current techniques to
separate CM’s EV and soluble proteins, we can conclude that the
partial effect ofMSC soluble factors on B cell immunomodulation
is preferentially induced not by EV but rather by the protein-
enriched fractions. The actual factors responsible of the effect are
still under investigation.
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